ArticleScientific reports2025
Microwave assisted synthesis and bioactive potential of folic acid functionalized tellurium nanoparticles (FA@Te NPs) against HeLa cancer cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chemotherapy is currently one of the most effective treatments for cancer, but it is often accompanied by nonspecific toxicity and drug resistance. Nanostructures, particularly tellurium-based ones, have anticancer potential, but further research is needed to determine their biological activities. Adding targeting molecules to such nanoparticles, such as folic acid, may increase their efficacy and selectivity. This study focused on the synthesis of folic acid-incorporated tellurium nanoparticles (FA@Te NPs) using a microwave-assisted method involving a K2TeO3 solution (1 mM) with NaBH4 and folic acid. The synthesized nanoparticles were analyzed using various techniques such as UV-visible spectroscopy, scanning electron microscopy (SEM), energy dispersive X-ray spectroscopy (EDS), X-ray diffraction (XRD), and Fourier transform infrared spectroscopy (FTIR). The nanoparticles, predominantly hexagonal and ranging in size from 3.9 nm to 11 nm, were then subjected to in vitro tests to assess their antioxidant activities, hemocompatibility, and cytotoxic effects. The FA@Te NPs demonstrated superior DPPH scavenging activity compared to bare Te NPs across concentrations from 20 µg/mL to 1280 µg/mL. Hemolytic tests revealed that FA@Te NPs had a significantly higher hemolytic potential than Te NPs at concentrations between 20 and 40 µg/mL. The IC50 values for HeLa cells treated with FA@Te NPs, Te NPs, and Cisplatin for 24 h were found to be 767.6 ± 8.8 µg/mL, 1399.5 ± 5.2 µg/mL, and 142.7 ± 4.6 µg/mL, respectively. Exposure to IC50 concentrations of FA@Te NPs and Te NPs resulted in a significant increase in necrosis and late-stage apoptosis in HeLa cells, highlighting the strong cytotoxicity of these nanoparticles. Further research is needed to understand the biological mechanisms underlying the activities of FA@Te NPs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.